Akanda (AKAN) Shares Outstanding (Weighted Average) (2020 - 2025)
Akanda's (AKAN) quarterly Shares Outstanding (Weighted Average) came in at $73.6 million in Q4 2025, up 16.17% YoY from $63.3 million in Q4 2024, and up 15.58% on a QoQ basis from $63.6 million in Q2 2025.
Akanda (AKAN) Shares Outstanding (Weighted Average) (2020 - 2025) Analysis & Trends
Akanda's Shares Outstanding (Weighted Average) history runs 6 years deep, the most recent figure standing at $73.6 million for Q4 2025.
- On a quarterly basis, Shares Outstanding (Weighted Average) rose 16.17% year-over-year to $73.6 million in Q4 2025; TTM through Dec 2025 was $73.6 million, a 16.17% increase from a year earlier, with the FY2025 full-year figure at $73.6 million, up 16.17% from the prior year.
- Shares Outstanding (Weighted Average) was $73.6 million for Q4 2025 at Akanda, up from $63.6 million in the prior quarter.
- Over the last five years, Shares Outstanding (Weighted Average) for AKAN reached as high as $73.6 million in Q4 2025 and fell as low as $50188.5 in Q2 2023.
- A 5-year average of $46.4 million and a median of $51.0 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
- The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) sank 99.89%; it then jumped 123359.76% in 2024.
- Tracing AKAN's Shares Outstanding (Weighted Average) over 5 years: stood at $7.3 million in 2021, then soared by 581.32% to $49.4 million in 2022, then rose by 3.21% to $51.0 million in 2023, then climbed by 24.11% to $63.3 million in 2024, then gained by 16.17% to $73.6 million in 2025.
- According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $73.6 million, $63.6 million, and $63.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 100.50 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | 5.11 Bn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | 64.74 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 88.01 Mn |
| 10 | Akanda | 1.34 Bn | 1.34 Bn | - | 73.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.56 Mn |
| Jun 30, 2025 | 63.64 Mn |
| Dec 31, 2024 | 63.32 Mn |
| Jun 30, 2024 | 61.96 Mn |
| Dec 31, 2023 | 51.02 Mn |
| Jun 30, 2023 | 50,188.45 |
| Dec 31, 2022 | 49.43 Mn |
| Jun 30, 2022 | 47.10 Mn |
| Dec 31, 2021 | 7.26 Mn |
| Dec 31, 2020 | 13.13 Mn |